Arialys Therapeutics
PrivateLast Round
Seed
Sep 12, 2023
Total Funding Raised
$58M
Company Overview
Arialys Therapeutics is a biotechnology company that develops precision medicines to treat autoimmune neuropsychiatric diseases by blocking pathogenic autoantibodies in the brain.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Arialys Therapeutics Comparables
Compare Arialys Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Santa Ana Bio | 63% | |
| STALICLA | 62% | |
| Roche Holding | 61% |
Arialys Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Sep 12, 2023 |
Key People
Founding team and executive leadership
Arialys Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| MPM BioImpact | Seed |
| Alexandria Venture Investments | Seed |
| Catalys Pacific | Seed |
| Avalon BioVentures | Seed |
| Johnson & Johnson Innovation – JJDC | Seed |
| Johnson & Johnson Innovation - JJDC, Inc. | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 12, 2023
$58M round led by Johnson & Johnson Innovation and Avalon BioVentures.
Arialys Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access